Table 4 Sensitivity analysis: NF-κB staining and ovarian tumor survival outcomes, the VUMC TROC

 Among all cases (N = 196)

1.94 (1.39–2.71)

< 0.001

1.73 (1.24–2.43)

0.001

 Among chemotherapy naïve cases (N = 190)

2.00 (1.42–2.81)

< 0.001

1.83 (1.30–2.58)

< 0.001

 Among invasive cases (N = 177)

1.71 (1.21–2.42)

0.002

1.61 (1.14–2.29)

0.007

 Among serous cases (N = 143)

1.98 (1.34–2.92)

< 0.001

1.90 (1.27–2.83)

0.002

 Among late stage cases (N = 137)

1.68 (1.14–2.47)

0.009

1.63 (1.10–2.41)

0.014

 Among invasive serous cases (N = 131)

1.89 (1.27–2.83)

0.002

1.91 (1.26–2.89)

0.003

 Among late stage serous cases (N = 119)

1.84 (1.21–2.81)

0.005

1.81 (1.17–2.80)

0.008

 Among high-grade serous cases (N = 118)

1.87 (1.21–2.87)

0.005

1.69 (1.09–2.62)

0.018

 Among all cases (N = 196)

1.31 (0.94–1.82)

0.113

1.30 (0.93–1.81)

0.127

 Among chemotherapy naïve cases (N = 190)

1.31 (0.93–1.83)

0.118

1.31 (0.93–1.85)

0.117

 Among invasive cases (N = 177)

1.33 (0.95–1.88)

0.100

1.33 (0.94–1.89)

0.108

 Among serous cases (N = 143)

1.04 (0.71–1.52)

0.860

1.20 (0.82–1.78)

0.352

 Among late stage cases (N = 137)

1.34 (0.93–1.93)

0.119

1.23 (0.85–1.77)

0.265

 Among invasive serous cases (N = 131)

1.15 (0.78–1.69)

0.482

1.30 (0.88–1.94)

0.193

 Among late stage serous cases (N = 119)

1.33 (0.89–1.99)

0.160

1.29 (0.86–1.93)

0.214

 Among high-grade serous cases (N = 118)

0.96 (0.63–1.47)

0.841

1.09 (0.71–1.69)

0.168